| Dr Gretchen Mary Sewczak-claude, PT, DPT | |
|
3125 E Grand Ave, Laramie, WY 82070-5137 | |
| (307) 742-3110 | |
| Not Available |
| Full Name | Dr Gretchen Mary Sewczak-claude |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 17 Years |
| Location | 3125 E Grand Ave, Laramie, Wyoming |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760680821 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1226 (Wyoming) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blair Investments Inc | 9234161035 | 14 |
News Archive
Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.
Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases.
The gonad is well known to be important for reproduction but also affects animal life span. Removal of germ cells - the sperm and egg producing cells - increases longevity of the roundworm Caenorhabditis elegans. However, the underlying molecular mechanisms were a mystery. Now scientists at the Cologne-based Max Planck Institute for Biology of Ageing, have discovered that germ cell removal flips a "molecular switch" that extends the life span by using components of a "developmental clock".
Kinetic Concepts, Inc. today announced it has received reimbursement approval from Japan's Health Insurance Bureau for use of the innovative V.A.C. ATS® Therapy System in the country. The approval signifies an important advancement in the company's plans for market launch in April and follows Japan's Ministry of Health, Labor and Welfare's decision in November 2009 to grant final regulatory approval for the product.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 3 days ago
| Provider Name | Blair Investments Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1912052242 PECOS PAC ID: 9234161035 Enrollment ID: O20050831000989 |
News Archive
Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.
Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases.
The gonad is well known to be important for reproduction but also affects animal life span. Removal of germ cells - the sperm and egg producing cells - increases longevity of the roundworm Caenorhabditis elegans. However, the underlying molecular mechanisms were a mystery. Now scientists at the Cologne-based Max Planck Institute for Biology of Ageing, have discovered that germ cell removal flips a "molecular switch" that extends the life span by using components of a "developmental clock".
Kinetic Concepts, Inc. today announced it has received reimbursement approval from Japan's Health Insurance Bureau for use of the innovative V.A.C. ATS® Therapy System in the country. The approval signifies an important advancement in the company's plans for market launch in April and follows Japan's Ministry of Health, Labor and Welfare's decision in November 2009 to grant final regulatory approval for the product.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gretchen Mary Sewczak-claude, PT, DPT 4111 Bobolink Ln, Laramie, WY 82070-5525 Ph: (303) 319-3803 | Dr Gretchen Mary Sewczak-claude, PT, DPT 3125 E Grand Ave, Laramie, WY 82070-5137 Ph: (307) 742-3110 |
News Archive
Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.
Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases.
The gonad is well known to be important for reproduction but also affects animal life span. Removal of germ cells - the sperm and egg producing cells - increases longevity of the roundworm Caenorhabditis elegans. However, the underlying molecular mechanisms were a mystery. Now scientists at the Cologne-based Max Planck Institute for Biology of Ageing, have discovered that germ cell removal flips a "molecular switch" that extends the life span by using components of a "developmental clock".
Kinetic Concepts, Inc. today announced it has received reimbursement approval from Japan's Health Insurance Bureau for use of the innovative V.A.C. ATS® Therapy System in the country. The approval signifies an important advancement in the company's plans for market launch in April and follows Japan's Ministry of Health, Labor and Welfare's decision in November 2009 to grant final regulatory approval for the product.
Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.
› Verified 3 days ago
Deanna Suder, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1771 Centennial Dr, 220, Laramie, WY 82070 Phone: 307-742-3571 | |
Jeri Black-farber, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1909 Vista Dr, Laramie, WY 82070 Phone: 307-745-8851 Fax: 307-742-0961 | |
Reed L Pedrick, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3125 E Grand Ave, Suite A, Laramie, WY 82070 Phone: 307-742-3110 | |
Lori J Franc, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1909 Vista Dr, Laramie, WY 82070 Phone: 307-745-8851 Fax: 607-742-0961 | |
James Boo, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1575 N 4th St Ste 101, Laramie, WY 82072 Phone: 307-745-5434 | |
Kendra Evans, DPT, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3125 E Grand Ave, Laramie, WY 82070 Phone: 307-742-3110 | |
Michael Zelyez, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1909 Vista Dr, Laramie, WY 82070 Phone: 307-721-8024 |